Royalty Pharma
RPRX
RPRX
377 hedge funds and large institutions have $9.23B invested in Royalty Pharma in 2024 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 160 increasing their positions, 113 reducing their positions, and 48 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
8% less capital invested
Capital invested by funds: $10B → $9.23B (-$810M)
11.92% less ownership
Funds ownership: 79.98% → 68.05% (-12%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
377
Holding in Top 10
7
Calls
$15.3M
Puts
$10.7M
Top Buyers
| 1 | +$90M | |
| 2 | +$78.4M | |
| 3 | +$60.4M | |
| 4 |
NSCM
New South Capital Management
Memphis,
Tennessee
|
+$43.1M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$41.2M |
Top Sellers
| 1 | -$1.43B | |
| 2 | -$154M | |
| 3 | -$70.2M | |
| 4 |
Goldman Sachs
New York
|
-$66.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$48.3M |